Comparative Pharmacology
Head-to-head clinical analysis: DONEPEZIL HYDROCHLORIDE versus EXELON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DONEPEZIL HYDROCHLORIDE versus EXELON.
DONEPEZIL HYDROCHLORIDE vs EXELON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reversible inhibitor of acetylcholinesterase, increasing acetylcholine concentration in the synaptic cleft of the central nervous system.
Exelon (rivastigmine) is a reversible, non-competitive acetylcholinesterase and butyrylcholinesterase inhibitor, increasing acetylcholine levels in the brain.
Alzheimer's disease: Initial 5 mg orally once daily at bedtime for 4-6 weeks, increase to 10 mg once daily. Maximum dose 10 mg/day.
Initial: 1.5 mg orally twice daily; after 2 weeks increase to 3 mg twice daily; then after 2 weeks increase to 4.5 mg twice daily; then after 2 weeks increase to 6 mg twice daily (maximum). For transdermal patch: initial 4.6 mg/24 hr applied once daily; after 4 weeks increase to 9.5 mg/24 hr; may increase to 13.3 mg/24 hr after additional 4 weeks.
None Documented
None Documented
Terminal elimination half-life approximately 70 hours (range 50-100 hours), allowing once-daily dosing; steady-state reached in 14-21 days
Terminal half-life: ~1.5 hours; clinical context: tid dosing recommended due to rapid elimination.
Renal (26% unchanged), fecal (57%, primarily as metabolites via biliary excretion)
Renal (97%) with unchanged drug <1%; biliary/fecal as metabolites.
Category C
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor